The heart muscle is harmed in many conditions. The body naturally tries to compensate for this damage. When the compensation fails, heart failure can develop.
Many symptoms of HF are non-specific. A clinical assessment of symptoms, risk factors for HF, comorbidities and underlying health are required. Physical symptoms are usually moderate or mild in patients with heart failure, however, exercise is common.
The usual treatment for heart failure are medications, such as vasodilators, ACE inhibitors and beta blockers. Moreover, the medical record should show the treatment history of the patient and their family for at least a month, even if they are treated only for 24 h in an acute hospital ward. The usual treatment for acute decompensated heart failure (ADHF) is inotropic agents, such as (digoxin, hydralazine etc.), vasodilators, inotropes, or drugs like nitroprusside or furosemide.
Current treatment options for heart failure are not curative. Future research and new treatment options are needed that reduce the impact of heart failure by improving patient well-being or curing the disease.
Heart failure is a heart condition that describes a group of disorders that substantially impair heart function. Its symptoms are fatigue, shortness of breath, and palpitations. It is estimated that it affects 2–3% of the US population; however, heart failure presents differently for different people, depending on the presence of risk factors.
The number of people who suffer heart failure in each year in the United States is estimated to be about 461,200. The mean annual incidence rate of heart failure in this survey should be the approximate rate of new cases annually, as some may be hospitalized and others may be asymptomatic and undetected. Our estimate for the number of new cases of heart failure annually in the US is similar to estimates made by the American Heart Association.
Recent findings, medication was one of the most expensive out of all prescription medication purchases. Medications and prescription drugs were the largest purchases from the Medicare prescription out of pocket, however, there was a general distrust of medical insurance, and people seemed willing to pay out-of-pocket for prescription drugs, but not out-of-pocket for medications (especially if medications are considered 'non-medication' like blood thinners, etc.
Findings from a recent study indicated that at least some forms of heart failure, at least in familial forms, seem to run in families. Thus, genetic predisposition could contribute to the occurrence of this entity.
A minority of health services payers require detailed, comprehensive (in terms of the costs to patients) medication cost information. The majority do not. These payers should not restrict free information provided by the medical practice, and inpatient pharmacies that provide this information on the prescription should be recognized as an essential aspect of the medical delivery service to patients who would be willing to pay more for that service.
There are a lot of advances that have happened in treatment of heart failure, but only a few recent developments have been of significant long-term benefit to patients.
Results from a recent clinical trial, the primary cause of heart failure was hypertension (40%) and ischemic heart disease (25%). It was associated with coronary heart Disease (5/10). The majority of patients were older (72%) and male (56%) and ischemic heart disease was the cause of heart failure in the male population (p=0.005).
The patients who participated in the study, all of varying levels of disability, were mostly middle aged to elderly male patients at the end of their life. The patients' disease process was typically classified as either congestive heart failure, or coronary heart disease. They were all receiving medication including ACE inhibitor. A majority of the patients were taking beta blockers; however, use of ACE inhibitor or diuretic was not specified in all of the clinical studies nor in the data collected. All patients were being managed under a clinical pathway and provided with an opportunity to participate in a trial. The only data collected from these studies was the data related to medication costs. Many of the patients mentioned in the studies were using more than one medication.